$Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report$

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report

Bing Sun,1 Lijuan Ding,1 Shikai Wu,1 Xiangying Meng,1 Santai Song2 1Department of Radiotherapy, 2Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, People’s Republic of China Background: Everolimus, an inhibitor of the mammalian target of r...

Full description

Bibliographic Details
Main Authors:	Sun B, Ding LJ, Wu S, Meng XY, Song S
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-07-01
Series:	OncoTargets and Therapy
Subjects:	advanced breast cancer mTOR inhibitor HER2 fulvestrant
Online Access:	https://www.dovepress.com/combined-treatment-with-everolimus-and-fulvestrant-reversed-anti-her2--peer-reviewed-article-OTT

Similar Items

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series <sup>†</sup>
by: Armando Orlandi, et al.
Published: (2020-12-01)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
by: Junjie Li, et al.
Published: (2019-05-01)

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome
by: Indhuja Muthiah Vaikundaraja, et al.
Published: (2020-01-01)

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
by: Rusz O, et al.
Published: (2018-09-01)

The role of RICTOR downstream of receptor tyrosine kinase in cancers
by: Ahlem Jebali, et al.
Published: (2018-02-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
by: Overwater IE, et al.
Published: (2019-07-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)

Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities
by: Julio Pascual, et al.
Published: (2017-05-01)

Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects
by: Simona Granata, et al.
Published: (2016-05-01)

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
by: Patrick Neven, et al.
Published: (2021-08-01)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
by: Fabio Gelsomino, et al.
Published: (2020-05-01)

Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
by: Gennatas Constantine, et al.
Published: (2012-09-01)

mTOR Inhibitors in Advanced Biliary Tract Cancers
by: Chao-En Wu, et al.
Published: (2019-01-01)

Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
by: L Yu Vladimirova
Published: (2016-12-01)

Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
by: Eui Joo Kim, et al.
Published: (2020-11-01)

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
by: Ryan W. Holloway, et al.
Published: (2021-06-01)

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
by: Alyssa Schlotman, et al.
Published: (2020-03-01)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
by: Li Y, et al.
Published: (2020-06-01)

Emerging use of everolimus in the treatment of neuroendocrine tumors
by: Gajate P, et al.
Published: (2017-06-01)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
by: Xu L, et al.
Published: (2018-11-01)

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study
by: Yao JC, et al.
Published: (2019-02-01)

EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
by: Rocca A, et al.
Published: (2018-08-01)

Everolimus in Anaplastic Thyroid Cancer: A Case Series
by: Ethan J. Harris, et al.
Published: (2019-02-01)

Everolimus improved renal function without reducing the size of a kidney angiomyolipoma in a patient with tuberous sclerosis complex: a case report
by: Akira Ashida, et al.
Published: (2018-06-01)

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
by: H. Hawle, et al.
Published: (2010-04-01)

Dose-dependent Effects of mTOR Inhibition on Weight and Mitochondrial Disease in Mice
by: Simon C Johnson, et al.
Published: (2015-07-01)

mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
by: Zongbi Yi, et al.
Published: (2020-08-01)

Fulvestrant in treatment for metastatic breast cancer
by: L. Yu. Vladimirova, et al.
Published: (2019-12-01)

Two cases of eczematous eruptions caused by everolimus
by: Minako Habu, et al.
Published: (2019-10-01)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
by: Mi Hwa Heo, et al.
Published: (2019-09-01)

Effect of the prenatal action of fulvestrant on the ovaries of the offspring of laboratory mice
by: Rimma T. Sulaymanova
Published: (2021-12-01)

Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study
by: Ute Eisenberger, et al.
Published: (2018-06-01)

Antimycobacterial Effects of Everolimus in a Human Granuloma Model
by: David Ashley, et al.
Published: (2020-06-01)

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
by: Andrew J. Browne, et al.
Published: (2017-08-01)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
by: Mathias Alrø Fichtner Bendtsen, et al.
Published: (2017-08-01)

Autophagy as a Vital Therapy Target for Renal Cell Carcinoma
by: Ying-hua He, et al.
Published: (2021-02-01)